Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 2INTERVENTIONAL

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

The Impact of Inhaled Treprostinil on Dyspnea and Exercise Intolerance in Mild COPD; a Pilot and Feasibility Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted Who Should NOT Join This Trial: - Pre-existing heart failure and pulmonary artery hypertension. - Known thrombocytopenia. - Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic. - Known sensitivity to prostanoids - Severe hepatic insufficiency Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted Exclusion Criteria: * Pre-existing heart failure and pulmonary artery hypertension. * Known thrombocytopenia. * Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic. * Known sensitivity to prostanoids * Severe hepatic insufficiency

Treatments Being Tested

DRUG

Placebo

Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCT

Treprostinil Inhalation Solution 36 mcg

Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCT

Treprostinil Inhalation Solution 78 mcg

Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

Locations (1)

Clinical Physiology Laboratory
Edmonton, Alberta, Canada